 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
218 News |  |
| «123» |
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity. (Pubmed Central) - May 12, 2022
Luseogliflozin may suppress cardiac hypertrophy in diabetes by reducing Tgf-β2 expression in cardiomyocytes via the suppression of NHE-1 activity.
- | Retrospective data, Journal: Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. (Pubmed Central) - May 6, 2022
Luseogliflozin may suppress cardiac hypertrophy in diabetes by reducing Tgf-β2 expression in cardiomyocytes via the suppression of NHE-1 activity. In patients with T2DM, compared with pure SGLT2 inhibitors, combined SGLT1/2 inhibitors demonstrated a lower risk of myocardial infarction and of stroke, but were associated with a higher risk of diarrhea and severe hypoglycemia.
- | Apleway (tofogliflozin) / Kowa, Takeda, Lusefi (luseogliflozin) / Taisho
Journal: Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. (Pubmed Central) - Apr 28, 2022
In MT-2 cells, both of SGLT2 inhibitors considerably attenuated glucose uptake, intracellular ATP levels, and NADPH production, resultantly enhancing cell cycle arrest at the G0/G1 phase. From the standpoint of metabolic oncology, the present study suggests that SGLT2 inhibitors would be a promising adjunctive option for the treatment of the most intractable human hematological malignancies like ATL.
- | Lusefi (luseogliflozin) / Taisho
Observational data, Journal: Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study. (Pubmed Central) - Apr 19, 2022
From the standpoint of metabolic oncology, the present study suggests that SGLT2 inhibitors would be a promising adjunctive option for the treatment of the most intractable human hematological malignancies like ATL. Luseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits.
- | Journal: Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. (Pubmed Central) - Apr 5, 2022
In addition, for T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight. This was the first study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Review, Journal: Effects of SGLT-2 inhibitors on serum uric acid in patients with T2DM: A systematic review and network meta-analysis. (Pubmed Central) - Apr 1, 2022
SGLT-2 inhibitors could significantly reduce SUA levels in patients with T2DM, especially luseogliflozin (1 mg and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT-2 inhibitors look extremely promising as an anti-diabetes treatment option in patients with T2DM with high SUA.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Review, Journal: Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 30, 2022
SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Total MD = -34.07 μmol/L, 95% CI [-37.00, -31.14]).
- | Lusefi (luseogliflozin) / Taisho
Journal: Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. (Pubmed Central) - Mar 26, 2022
Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. (Pubmed Central) - Mar 24, 2022
Intramuscular fatty acid metabolism and gene expression were influenced by the extracellular lipidome, which was modified by SGLT2i. Hence, secondary effects, other than the hypoglycaemic effects of SGLT2i, might lead to the alleviation of sarcopenia.
- | Lusefi (luseogliflozin) / Taisho
Journal: Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. (Pubmed Central) - Mar 23, 2022
University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) number: UMIN000045003. Japan Registry of Clinical Trials registration number: jRCTs061210009.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Factors Influencing Change in Serum Uric Acid after Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus. (Pubmed Central) - Mar 5, 2022
Treatment with luseogliflozin resulted in increased serum uric acid in some patients, which may be due to reduced glomerular filtration of uric acid via the tubuloglomerular feedback. SGLT2 inhibitors reduced serum uric acid desirably in patients with T2DM with low HbA1c and high serum uric acid.
- | Lusefi (luseogliflozin) / Taisho
Journal: Luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-month-old diabetic animals. (Pubmed Central) - Feb 19, 2022
However, SGLT2i did not have direct constrictive effects on vascular smooth muscle cells and MCAs isolated from normal rats, although it decreased reactive oxygen species production in cerebral vessels of DM rats. These results provide evidence that normalization of hyperglycemia with an SGLT2i can reverse cerebrovascular dysfunction and cognitive impairments in rats with long-standing hyperglycemia, possibly by ameliorating oxidative stress-caused vascular damage.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal, Head-to-Head: The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan. (Pubmed Central) - Feb 1, 2022
These results provide evidence that normalization of hyperglycemia with an SGLT2i can reverse cerebrovascular dysfunction and cognitive impairments in rats with long-standing hyperglycemia, possibly by ameliorating oxidative stress-caused vascular damage. Three SGLT2Is with no CVOT's evidence did not show noninferiority compared with other SGLT2Is with evidences.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin. (Pubmed Central) - Dec 22, 2021
Luseogliflozin monotherapy resulted in an improvement in blood glucose, a decrease in body weight, and decreased insulin resistance. Luseogliflozin appears to be an effective therapy for obese diabetics.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Effect of Treatment With Sodium-Glucose Cotransporter 2 Inhibitor on the Initiation of Continuous Positive Airway Pressure Therapy in Type 2 Diabetic Patients With Obstructive Sleep Apnea Syndrome. (Pubmed Central) - Dec 21, 2021
The body weight and BMI increased significantly after 3 months of CPAP therapy initiated for OSAS in the type 2 diabetic patients who were receiving SGLT2 inhibitor therapy. Thus, when CPAP therapy is adopted for an obese diabetic patient with OSAS, it should be borne in mind that the body weight may increase if the patient is receiving SGLT2 inhibitor treatment.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: a multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). (Pubmed Central) - Nov 29, 2021
Thus, when CPAP therapy is adopted for an obese diabetic patient with OSAS, it should be borne in mind that the body weight may increase if the patient is receiving SGLT2 inhibitor treatment. Switching from DPP-4i to luseogliflozin decreased nighttime SBP and PR; moreover, BP circadian rhythm was improved.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Review, Journal: Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review. (Pubmed Central) - Oct 20, 2021
The review showed that SGLT2 inhibitors have adverse reactions similar to that of a placebo, with a slight increase in treatable genital mycotic and urinary tract infections but no evidence of diabetic ketoacidosis, fractures, and amputations. According to the available data, SGLT2 inhibitors can significantly prevent or reduce cardiovascular diseases and kidney abnormalities in patients with type 2 diabetes mellitus with tolerable safety outcomes.
- | Lusefi (luseogliflozin) / Taisho
Retrospective data, Journal: Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation. (Pubmed Central) - Oct 13, 2021
According to the available data, SGLT2 inhibitors can significantly prevent or reduce cardiovascular diseases and kidney abnormalities in patients with type 2 diabetes mellitus with tolerable safety outcomes. Luseogliflozin can preserve the renal function in the medium term in patients with type 2 diabetes and renal impairment without an increase in specific adverse events.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. (Pubmed Central) - Oct 8, 2021
The course of eGFR from 12 to 52 weeks was maintained regardless of acute changes. Although acute changes in eGFR varied widely among patients with type 2 diabetes, the course of eGFR thereafter was stable regardless of the degree of acute changes.
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Diet Intake Control Is Indispensable for the Gluconeogenic Response to Sodium-Glucose Cotransporter 2 Inhibition in Male Mice. (Pubmed Central) - Oct 6, 2021
Although acute changes in eGFR varied widely among patients with type 2 diabetes, the course of eGFR thereafter was stable regardless of the degree of acute changes. Food intake management is crucial for SGLT2i to affect glucose and energy metabolism during type 2 diabetes treatment.
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice. (Pubmed Central) - Sep 15, 2021
In conclusion, neither SGLT2 inhibition nor blood glucose level affect glucose uptake kinetics in PTs. The former was because of glucose influx through basolateral GLUT2, which is an established bidirectional transporter.
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. (Pubmed Central) - Aug 18, 2021
Treatment with an SGLT2 inhibitor, luseogliflozin (10 mg/kg/day, p.o., n = 7), significantly attenuated the HSD-induced elevation of MAP, which was associated with a reduction in LF of SAP. These data suggest that treatment with an SGLT2 inhibitor attenuates the salt sensitivity of BP, which is associated with SNA inhibition in nondiabetic CKD rats.
- Lusefi (luseogliflozin) / Taisho
[VIRTUAL] Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes and hypertension (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_233;
Switching from DPP-4i to luseogliflozin decreased not only daytime but also nighttime SBP and PR, and improved BP circadian rhythm. These improvements could be some of the factors involved in the cardiovascular event suppression observed with SGLT2i therapy.
- | Lusefi (luseogliflozin) / Taisho
Preclinical, Journal: Failure to confirm an SGLT2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. (Pubmed Central) - Jul 8, 2021
These improvements could be some of the factors involved in the cardiovascular event suppression observed with SGLT2i therapy. These data suggest that SGLT2 inhibitor fails to exert hematopoietic effects in non-diabetic conditions.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes. (Pubmed Central) - Jun 10, 2021
Treatment with selective sodium-glucose cotransporter 2 inhibitors luseogliflozin was associated with changes of the vaginal flora. These findings provide basic data on the increased susceptibility to genital infections during luseogliflozin treatment.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Observational data, Journal: Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. (Pubmed Central) - Jun 8, 2021
The 2016-2017 increased prescription volume also varied among prefectures by as large as 7.3-fold for ipragliflozin. Regression analysis revealed that the annual and increased prescription volume of all the SGLT2 inhibitors except luseogliflozin were higher in regions with more certified cardiologists (P < 0.05), even after adjusting for regional parameters.In conclusion, the regional number of certified cardiologists was positively associated with a 2016 annual of and 2016-2017 increase in SGLT2 inhibitor prescription amount, implying an early adopter role of clinical experts in healthcare delivery.
- Lusefi (luseogliflozin) / Taisho
[VIRTUAL] Lowering of Blood Pressure and Pulse Rate by Switching from DPP-4 Inhibitor to Luseogliflozin in Patients with Type 2 Diabetes and Hypertension: A Multicenter, Prospective, Randomized, Open-Label, Parallel-Group Comparison Trial () - May 29, 2021 - Abstract #ADA2021ADA_1894;
Switching from DPP-4i to luseogliflozin decreased not only daytime but also nighttime SBP and PR, and improved BP circadian rhythm. These improvements could be some of the factors involved in the cardiovascular event suppression observed with SGLT2i therapy.
- Lusefi (luseogliflozin) / Taisho
[VIRTUAL] SGLT2 Inhibitor, Luseogliflozin, Prevent Sarcopenia by Improving Extracellular Lipidome () - May 29, 2021 - Abstract #ADA2021ADA_1189;
The administration of luseogliflozin suppressed skeletal muscle atrophy and reduced the concentration of saturated fatty acids in skeletal muscle. Based on these findings, we hypothesized that secondary effects, other than the hypoglycemic effects of SGLT2i, might lead to the alleviation of obesity-dependent sarcopenia.
- Lusefi (luseogliflozin) / Taisho
[VIRTUAL] Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor () - May 29, 2021 - Abstract #ADA2021ADA_1186;
(data not shown) Although the result is a new aspect of SGLT2 inhibitor, the clinical significance is not clear. Since Risso A et al reported that glycemic fluctuation cause harm to vascular endothelial cells (AJP 2001), SGLT2 inhibitors may reduce damage of blood vessel via regulation of fine glycemic fluctuation.
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
[VIRTUAL] Efficacy of SGLT2 Inhibitor on Circulating Advanced Glycation End Products in Japanese Patients with Type 2 Diabetes () - May 29, 2021 - Abstract #ADA2021ADA_1176;
In contrast, DPP-4i little changed in MG-H1 and blood biochemical parameters except for reduction of HbA1c (P<0.05). Comparing DPP-4i, the present study demonstrates that SGLT2i has superiority on improvement of AGEs level in patients with type 2 diabetes while detailed mechanisms of this effect are not clear.
- Lusefi (luseogliflozin) / Taisho
[VIRTUAL] Improved Mitochondrial Function by Luseogliflozin Prevents Pancreatic Beta-Cell Damage () - May 29, 2021 - Abstract #ADA2021ADA_1166;
Relief of glucotoxicity by luseogliflozin may reduce mitochondrial ROS generation and elevate Nkx6.1 expression related to beta cell proliferation. The elevated expression of Nkx6.1 could improve glucose metabolism in the TCA cycle, resulting in protection of beta cells.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study. (Pubmed Central) - May 27, 2021
The reduction in morning home systolic BP was ≥ 5 mm Hg and was independent of baseline BP and BP control status. In conclusion, there was no change in arterial stiffness (based on CAVI) during treatment with luseogliflozin, but changes in BP and metabolic parameters were consistent with the known beneficial effects of SGLT2 inhibitors in T2DM.
- Lusefi (luseogliflozin) / Taisho
Trial of a mouse model of progressive diabetic nephropathy and examination of its effect of preventing its progression by Luseogliflozin (Venue 5 3rd floor G316 + G317) - May 26, 2021 - Abstract #JSN2021JSN_168;
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. (Pubmed Central) - Apr 14, 2021
The results will be disseminated in peer-reviewed journals and at scientific conferences. The University Hospital Medical Information Network (UMIN000031451); Japan Registry of Clinical Trials (jRCTs011180019); Pre-results.
- | Lusefi (luseogliflozin) / Taisho
Journal: Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. (Pubmed Central) - Apr 2, 2021
The University Hospital Medical Information Network (UMIN000031451); Japan Registry of Clinical Trials (jRCTs011180019); Pre-results. These results suggest that luseogliflozin can increase beta cell proliferation through the activation of the FoxM1/PLK1/CENP-A pathway via humoral factors that act in an insulin/IGF-1 receptor-independent manner.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Efficacy of Semaglutide by Background Sodium – Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9 (Channel 4) - Mar 21, 2021 - Abstract #DDG2021DDG_469;
SUSTAIN 9 investigated semaglutide 1.0 mg vs placebo as add-on to a stable dose of sodium-glucose co transporter-2 inhibitor (SGLT-2i) therapy, with or without metformin or a sulfonylurea...In this post hoc analysis, SUSTAIN 9 data were analyzed by background SGLT-2i (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])...In conclusion, in subjects with T2D already receiving an SGLT-2i, semaglutide generally resulted in superior HbA1c and body weight reductions vs placebo, regardless of background SGLT-2i therapy. Joachim Kienhöfer is just presenting on behalf of the author group (Sponsored by Novo Nordisk A / S).
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. (Pubmed Central) - Mar 10, 2021
Conclusion In patients with type 2 diabetes mellitus and HFpEF, there is no significant difference in the degree of reduction in BNP concentrations after 12 weeks between luseogliflozin and voglibose. Registration URL: https://www.umin.ac.jp/ctr/index.htm; Unique identifier: UMIN000018395.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. (Pubmed Central) - Feb 18, 2021
Registration URL: https://www.umin.ac.jp/ctr/index.htm; Unique identifier: UMIN000018395. Luseogliflozin administration in patients with T2DM complicated by hepatic dysfunction was well tolerated, did not worsen the hepatic condition, and might even be beneficial to improve hepatic function, reduce liver fat, and attenuate liver injury and fibrosis.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT). (Pubmed Central) - Jan 30, 2021
Besides, metformin is considered to have a neutral effect on bone. This trial should reveal the effect of luseogliflozin on bone metabolism in older patients with T2DM.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. (Pubmed Central) - Jan 21, 2021
SGLT2 inhibitors also reduce liver fat in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. This chapter describes the basic information about SGLT2 inhibitors, current status of SGLT2 inhibitors in the management of type 2 diabetes and their beneficial effects in addition to glycemic control.
- || Lusefi (luseogliflozin) / Taisho
Clinical, Journal: Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor. (Pubmed Central) - Dec 30, 2020
These results suggest that the combination therapy is useful, in particular, for the treatment of type 2 diabetes mellitus patients with hyperlipidemia and liver dysfunction. Among the SGLT2 inhibitors added to the DPP-4 inhibitor treatment, the decreases of serum levels of AST, ALT and γ-GTP were particularly significant in the group receiving luseogliflozin, suggesting that the combination of a DPP-4 inhibitor with luseogliflozin is particularly effective for the treatment of type 2 diabetes mellitus patients with liver dysfunction.
- | Lusefi (luseogliflozin) / Taisho
Journal: Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. (Pubmed Central) - Nov 19, 2020
This case demonstrates that long-term luseogliflozin may be a good therapeutic option for diabetic NAFLD/NASH patients. The merits of persistent SGLT2I administration for NAFLD/NASH patients warrant validation in future studies.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. (Pubmed Central) - Nov 12, 2020
Canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin are known to be SGLT-2 inhibitors. Herein, we discussed the current and future aspects of the development and applications of SGLT-2 inhibitors.
- | Lusefi (luseogliflozin) / Taisho
Journal: Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. (Pubmed Central) - Nov 2, 2020
Together, luseogliflozin inhibits hypoxia-induced HIF-1α accumulation by suppressing mitochondrial oxygen consumption. The SGLT2 inhibitors may protect diabetic kidneys by therapeutically targeting HIF-1α protein.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Review, Journal: Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations. (Pubmed Central) - Sep 30, 2020
A series of clinical recommendations on the use of SGLT-2 inhibitors in Asian patients with T2DM were deliberated amongst experts with multiple rounds of review and voting. Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of HF hospitalization and secondary prevention of CVD in patients with T2DM and should be considered early in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
- Lusefi (luseogliflozin) / Taisho
The nephroprotective effect of Luceogliflozin in patients with type 2 diabetes depends on the underlying renal function () - Aug 30, 2020 - Abstract #JSN2020JSN_920;
However, the changes in the low value group were mild. Urine protein improved in all groups.
- Lusefi (luseogliflozin) / Taisho
Changes in glomerular hemodynamics induced by SGLT2 inhibitors and its mechanism in type 2 diabetes model animals () - Aug 30, 2020 - Abstract #JSN2020JSN_154;
SGLT2i (luseogliflozin) group, SGLT2i+A1aR antagonist group, and insulin group were prepared, and changes in blood vessel diameter, SNGFR, blood glucose, and urinary Na excretion up to 120 minutes after administration were observed...Urinary Na excretion was similar in both groups using SGLT2i. [Discussion] In glomerular hyperfiltration in type 2 diabetes mellitus, TGF via adenosine/A1aR pathway is involved, and it is involved in inhibition of glomerular hyperfiltration by SGLT2 inhibition.
- ||| Lusefi (luseogliflozin) / Taisho, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical: Indeed, we await reporting on these 2 trials on dapagliflozin & empagliflozin vs placebo in hfpef. I suspect the small trial that @MiguelCamafort tweeted about (luseogliflozin vs voglibose) will also be followed by an adequately powered one, tho don’t see one registered. (Twitter) - Aug 2, 2020
- |||| Lusefi (luseogliflozin) / Taisho
Clinical: Open Label RCT, n:173, T2DM & HFpEF, NO significant difference in reduction in BNP concentrations after 12 w between luseogliflozin and voglibose. Waiting for Blind RCT with hard endpoints in HFPEF! @gcfmd @JavedButler1 @NMHheartdoc @ShelleyZieroth @hvanspall @YMareev (Twitter) - Aug 2, 2020
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Review, Journal: Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. (Pubmed Central) - Jul 28, 2020
[Discussion] In glomerular hyperfiltration in type 2 diabetes mellitus, TGF via adenosine/A1aR pathway is involved, and it is involved in inhibition of glomerular hyperfiltration by SGLT2 inhibition. Preclinical studies indicate that SGLT-2 inhibitors attenuate vascular dysfunction in preclinical models via a combination of mechanisms that appear to act independently of glucose-lowering benefits.